SCHEMBL1687746

SCHEMBL1687746

c1ccc2c(c1)sc1ccc(-c3ccc(-c4ccc(-n5c6ccccc6c6cc(-n7c8ccccc8c8ccccc87)ccc65)cc4)cc3)cc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
ATM Q13315 1/20 0.42
GPR3 P46089 1/20 0.39
HDAC4 P56524 1/20 0.36
MAPT P10636 3/20 0.34
ALDH1A1 P00352 2/20 0.34
HPGD P15428 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
TSPO P30536 2/20 0.34
PIM3 Q86V86 1/20 0.33
CYP1A2 P05177 1/20 0.33
HSD17B10 Q99714 1/20 0.33
EDNRB P24530 1/20 0.32
EDNRA P25101 1/20 0.32
PTPN7 P35236 1/20 0.32
DUSP3 P51452 1/20 0.32
PTPN12 Q05209 1/20 0.32
PTPN22 Q9Y2R2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17885344 1.00 KDM4E (0.42) KDM4EL3MBTL1ATMGPR3HDAC4
SCHEMBL14868014 1.00 KDM4E (0.42) KDM4EL3MBTL1ATMGPR3HDAC4
SCHEMBL24677126 1.00 KDM4E (0.42) KDM4EL3MBTL1ATMGPR3HDAC4
SCHEMBL16171580 0.99 KDM4E (0.43) KDM4EL3MBTL1ATMGPR3HDAC4
SCHEMBL20706735 0.99 GPR3 (0.40) KDM4EL3MBTL1ATMGPR3HDAC4
SCHEMBL16804091 0.97 ATM (0.47) KDM4EL3MBTL1ATMGPR3HDAC4
SCHEMBL25941731 0.97 L3MBTL1 (0.44) KDM4EL3MBTL1ATMGPR3HDAC4
SCHEMBL21481440 0.97 L3MBTL1 (0.44) KDM4EL3MBTL1ATMGPR3HDAC4
SCHEMBL14212276 0.97 L3MBTL1 (0.44) KDM4EL3MBTL1ATMGPR3HDAC4
SCHEMBL25941224 0.97 L3MBTL1 (0.44) KDM4EL3MBTL1ATMGPR3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9401482-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2016-07-26 US disclosed
US-9401482-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2016-07-26 US disclosed
US-20150097176-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2015-04-09 US disclosed
US-20150097176-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2015-04-09 US disclosed
US-8932734-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2015-01-13 US disclosed
US-8932734-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2015-01-13 US disclosed
WO-2012048266-A1 NOVEL 3, 9-LINKED OLIGOCARBAZOLE-BASED HOSTS, CONTAINING DBT AND DBR FRAGMENTS, SEPARATED BY AROMATIC SPACERS UNIVERSAL DISPLAY CORPORATION (US) 2012-04-12 WO disclosed
US-20120086329-A1 Novel 3, 9-Linked Oliogocarbazole-Based Hosts, Containing DBT and DBF Fragments, Separated by Aromatic Spacers Universal Disolay Corporation (US) 2012-04-12 US disclosed
US-20120086329-A1 Novel 3, 9-Linked Oliogocarbazole-Based Hosts, Containing DBT and DBF Fragments, Separated by Aromatic Spacers Universal Disolay Corporation (US) 2012-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120086329-A1 Novel 3, 9-Linked Oliogocarbazole-Based Hosts, Containing DBT and DBF Fragments, Separated by Aromatic Spacers DBF4, OGFOD1, DDT KDM4E 1173/4885L3MBTL1 475/4885ATM 1916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.